Copyright
©The Author(s) 2025.
World J Gastroenterol. Mar 14, 2025; 31(10): 102289
Published online Mar 14, 2025. doi: 10.3748/wjg.v31.i10.102289
Published online Mar 14, 2025. doi: 10.3748/wjg.v31.i10.102289
Table 2 Cited clinical studies conducted to analyze the effectiveness of vonoprazan
| No. of patients | Group with vonoprazan (days) | Eradication | Control group (days) | Eradication | Identification | Ref. |
| 1046 | Vonoprazan 20 mg + amoxicillin 1 g + clarithromycin 500 mg (14 days) | 80.8%1 | Lansoprazole 30 mg + amoxicillin 1 g + clarithromycin 500 mg (14 days) | 68.5%1 | NCT04167670 | |
| 118 | Vonoprazan 20 mg + amoxicillin 1 g + clarithromycin 500 mg (7 days) | 96.7%1 | Omeprazole 20 mg + amoxicillin 1 g + clarithromycin 500 mg (14 days) | 88.5%1 | TCTR20210219007 | [134] |
| 600 | Vonoprazan 20 mg + amoxicillin 1 g (14 days) | 92.5%2 | Rabeprazole 20 mg + bismuth potassium citrate/tinidazole/clarithromycin, combined packet 4.2 g (14 days) | 81.5%2 | NCT05469685 | [32] |
| 234 | Vonoprazan 20 mg + amoxicillin 1 g + furazolidone 100 mg + bismuth 200 mg (10 days) | 96.2%1 | Esomeprazole 20 mg + amoxicillin 1000 mg + furazolidone 100 mg + bismuth 200 mg (14 days) | 93.6%1 | NCT04907747 | [136] |
- Citation: Rocha GR, Lemos FFB, Silva LGO, Luz MS, Correa Santos GL, Rocha Pinheiro SL, Calmon MS, de Melo FF. Overcoming antibiotic-resistant Helicobacter pylori infection: Current challenges and emerging approaches. World J Gastroenterol 2025; 31(10): 102289
- URL: https://www.wjgnet.com/1007-9327/full/v31/i10/102289.htm
- DOI: https://dx.doi.org/10.3748/wjg.v31.i10.102289